Adagrasib

Chemical formula: C₃₂H₃₅ClFN₇O₂  Molecular mass: 604.119 g/mol  PubChem compound: 138611145

Therapeutic indications

Adagrasib is indicated for:

Advanced non-small cell lung cancer with KRAS G12C mutation

Population group: only adults (18 years old or older)

Adagrasib as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Adagrasib is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Concomitant use of CYP3A substrates with a narrow therapeutic index

at least one of
CYP3A4 substrates
Cytochrome P-450 CYP3A5 substrates
and additionally Narrow Therapeutic Index Drugs (NTI)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: KRAZATI Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈